Venita De Almeida

- Advise on preclinical and clinical development strategy for oncology and chronic disease programs - Define and execute preclinical and regulatory packages for clinical candidates - Advise start-ups and academic spinouts on raising VC and non-dilutive funding - Due diligence for venture funding and in-licensing of preclinical and clinical assets

Program deveopment strategy

Program development for T cell engagers targeting pHLA targets

Led Preclinical Development group, comprising safety, PK, bioanalytical and biomarker functions

Led cross-functional team for the STRO-002 ADC development program into early Phase I studies. Authored and reviewed key regulatory submission documents.

Provided scientific support and influence overall strategy for internal development programs. Development of clinical strategy for early phase drug development of ADC candidates. Competitive landscape analysis and market projections, application to program strategy. Represented the Company at industry meetings and in collaborations with external partners.

Target selection for ADCs and bispecific molecules Design of product concepts, development strategy Due diligence efforts and new technology assessments. Preclinical safety, bioanalytical and biomarker analysis, diagnostic development.

Competitive analysis and strategy Product concept for bispecific therapeutics Target evaluation for Oncology therapeutics Technology evaluation for ADC development Product concept for peptide arrays in research and diagnostics

Regulation of glucose and fat metabolism. Wnt inhibitors in stem cell biology, as oncology therapeutics Validation of novel oncology targets for ADC programs

Elucidated role of GHRH receptor domains in ligand binding and signaling. Studied function of naturally occurring receptor isoforms and variants from patients with growth deficiency or pituitary tumors.